Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioLASCO Taiwan Co (6662) Fair Value & Analysis

Healthcare · TW · Market cap 773M TWD

Price29.80 TWD
Fair Value20.99 TWD
Upside-29.6%
Quality95/100
Evidence: High Range 15.27 TWD – 29.54 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

BioLASCO Taiwan Co (6662) currently trades at 29.80 TWD, while our model-based Fair Value estimate is 20.99 TWD — implying the stock looks roughly 29.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory animals in Taiwan and internationally. The company offers lab animals, such as rat, mice, and others, as well as surgical services; and rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system, and experimental equipment. It also offers reagents, including lab animal diagnostic reagent, endotoxin testing system, portable endotoxin testing system, rapid microbial detection, biological indicators, and iReal antibody; and various services, such as animal testing, pathology and toxicology, serological testing, lab animal center management services. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is BioLASCO Taiwan Co (6662) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 20.99 TWD versus a price of 29.80 TWD — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6662?
Our 21-model fair value for BioLASCO Taiwan Co is 20.99 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 29.80 TWD.
What is the quality score of 6662?
BioLASCO Taiwan Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.